Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 11/2015

01-11-2015 | Original Article

The influence of different peritoneal dialysis fluids on the in vitro activity of ampicillin, daptomycin, and linezolid against Enterococcus faecalis

Authors: M. Kussmann, L. Schuster, M. Zeitlinger, P. Pichler, G. Reznicek, M. Wiesholzer, H. Burgmann, W. Poeppl

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 11/2015

Login to get access

Abstract

Intraperitoneal administration of antibiotics is recommended for the treatment of peritoneal dialysis-related peritonitis. However, little data are available on a possible interference between peritoneal dialysis fluids and the activity of antimicrobial agents. Thus, the present in vitro study set out to investigate the influence of different peritoneal dialysis fluids on the antimicrobial activity of ampicillin, linezolid, and daptomycin against Enterococcus faecalis. Time–kill curves in four different peritoneal dialysis fluids were performed over 24 h with four different concentrations (1 × MIC, 4 × MIC, 8 × MIC, 30 × MIC) of each antibiotic evaluated. Cation-adjusted Mueller–Hinton broth was used as the comparator solution. All four peritoneal dialysis fluids evaluated had a bacteriostatic effect on the growth of Enterococcus faecalis. Compared to the cation-adjusted Mueller–Hinton broth comparator solution, the antimicrobial activity of all antibiotics tested was reduced. For ampicillin and linezolid, no activity was found in any peritoneal dialysis fluid, regardless of the concentration. Daptomycin demonstrated dose-dependent activity in all peritoneal dialysis fluids. Bactericidal activity was observed at the highest concentrations evaluated in Dianeal® PDG4 and Extraneal®, but not in concentrations lower than 30 × MIC and not in Nutrineal® PD4 and Physioneal® 40. The antimicrobial activity of ampicillin and linezolid is limited in peritoneal dialysis fluids in vitro. Daptomycin is highly effective in peritoneal dialysis fluids and might, thus, serve as an important treatment option in peritoneal dialysis-related peritonitis. Further studies are needed to evaluate the clinical impact of the present findings.
Literature
2.
go back to reference Li PK-T, Szeto CC, Piraino B, Bernardini J, Figueiredo AE, Gupta A et al (2010) Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int 30:393–423CrossRefPubMed Li PK-T, Szeto CC, Piraino B, Bernardini J, Figueiredo AE, Gupta A et al (2010) Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int 30:393–423CrossRefPubMed
3.
go back to reference Piraino B, Bernardini J, Brown E, Figueiredo A, Johnson DW, Lye W-C et al (2011) ISPD position statement on reducing the risks of peritoneal dialysis-related infections. Perit Dial Int 31:614–630CrossRefPubMed Piraino B, Bernardini J, Brown E, Figueiredo A, Johnson DW, Lye W-C et al (2011) ISPD position statement on reducing the risks of peritoneal dialysis-related infections. Perit Dial Int 31:614–630CrossRefPubMed
4.
go back to reference Salzer W (2005) Antimicrobial-resistant gram-positive bacteria in PD peritonitis and the newer antibiotics used to treat them. Perit Dial Int 25:313–319PubMed Salzer W (2005) Antimicrobial-resistant gram-positive bacteria in PD peritonitis and the newer antibiotics used to treat them. Perit Dial Int 25:313–319PubMed
5.
go back to reference Gorman T, Eisele G, Bailie GR (1995) Intraperitoneal antibiotics effectively treat non-dialysis-related infections. Perit Dial Int 15:283–284PubMed Gorman T, Eisele G, Bailie GR (1995) Intraperitoneal antibiotics effectively treat non-dialysis-related infections. Perit Dial Int 15:283–284PubMed
6.
go back to reference van Esch S, Krediet RT, Struijk DG (2014) 32 years’ experience of peritoneal dialysis-related peritonitis in a university hospital. Perit Dial Int 34:162–170PubMedCentralCrossRefPubMed van Esch S, Krediet RT, Struijk DG (2014) 32 years’ experience of peritoneal dialysis-related peritonitis in a university hospital. Perit Dial Int 34:162–170PubMedCentralCrossRefPubMed
7.
go back to reference Huang S-T, Chuang Y-W, Cheng C-H, Wu M-J, Chen C-H, Yu T-M et al (2011) Evolution of microbiological trends and treatment outcomes in peritoneal dialysis-related peritonitis. Clin Nephrol 75:416–425CrossRefPubMed Huang S-T, Chuang Y-W, Cheng C-H, Wu M-J, Chen C-H, Yu T-M et al (2011) Evolution of microbiological trends and treatment outcomes in peritoneal dialysis-related peritonitis. Clin Nephrol 75:416–425CrossRefPubMed
8.
go back to reference Cho Y, Johnson DW (2014) Peritoneal dialysis-related peritonitis: towards improving evidence, practices, and outcomes. Am J Kidney Dis 64:278–289CrossRefPubMed Cho Y, Johnson DW (2014) Peritoneal dialysis-related peritonitis: towards improving evidence, practices, and outcomes. Am J Kidney Dis 64:278–289CrossRefPubMed
9.
go back to reference Edey M, Hawley CM, McDonald SP, Brown FG, Rosman JB, Wiggins KJ et al (2010) Enterococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 116 cases. Nephrol Dial Transplant 25:1272–1278CrossRefPubMed Edey M, Hawley CM, McDonald SP, Brown FG, Rosman JB, Wiggins KJ et al (2010) Enterococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 116 cases. Nephrol Dial Transplant 25:1272–1278CrossRefPubMed
10.
go back to reference Huen SC, Hall I, Topal J, Mahnensmith RL, Brewster UC, Abu-Alfa AK (2009) Successful use of intraperitoneal daptomycin in the treatment of vancomycin-resistant enterococcus peritonitis. Am J Kidney Dis 54:538–541CrossRefPubMed Huen SC, Hall I, Topal J, Mahnensmith RL, Brewster UC, Abu-Alfa AK (2009) Successful use of intraperitoneal daptomycin in the treatment of vancomycin-resistant enterococcus peritonitis. Am J Kidney Dis 54:538–541CrossRefPubMed
11.
go back to reference Hassoun AA, Coomer RW, Mendez-Vigo L (2009) Intraperitoneal daptomycin used to successfully treat vancomycin-resistant enterococcus peritonitis. Perit Dial Int 29:671–673PubMed Hassoun AA, Coomer RW, Mendez-Vigo L (2009) Intraperitoneal daptomycin used to successfully treat vancomycin-resistant enterococcus peritonitis. Perit Dial Int 29:671–673PubMed
12.
go back to reference Song IJ, Seo JW, Kwon YE, Kim YL, Lim TS, Kang EW et al (2014) Successful treatment of vancomycin-resistant enterococcus peritonitis using linezolid without catheter removal in a peritoneal dialysis patient. Perit Dial Int 34:235–239PubMedCentralCrossRefPubMed Song IJ, Seo JW, Kwon YE, Kim YL, Lim TS, Kang EW et al (2014) Successful treatment of vancomycin-resistant enterococcus peritonitis using linezolid without catheter removal in a peritoneal dialysis patient. Perit Dial Int 34:235–239PubMedCentralCrossRefPubMed
13.
go back to reference The European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2015) Routine and extended internal quality control as recommended by EUCAST. Version 5.0, valid from 2015-01-09. Home page at: http://www.eucast.org The European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2015) Routine and extended internal quality control as recommended by EUCAST. Version 5.0, valid from 2015-01-09. Home page at: http://​www.​eucast.​org
14.
go back to reference Hermsen ED, Hovde LB, Hotchkiss JR, Rotschafer JC (2003) Increased killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate model. Antimicrob Agents Chemother 47:3764–3767PubMedCentralCrossRefPubMed Hermsen ED, Hovde LB, Hotchkiss JR, Rotschafer JC (2003) Increased killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate model. Antimicrob Agents Chemother 47:3764–3767PubMedCentralCrossRefPubMed
15.
go back to reference Tobudic S, Poeppl W, Kratzer C, Vychytil A, Burgmann H (2012) Comparative in vitro antimicrobial activity of vancomycin, teicoplanin, daptomycin and ceftobiprole in four different peritoneal dialysis fluids. Eur J Clin Microbiol Infect Dis 31:1327–1334CrossRefPubMed Tobudic S, Poeppl W, Kratzer C, Vychytil A, Burgmann H (2012) Comparative in vitro antimicrobial activity of vancomycin, teicoplanin, daptomycin and ceftobiprole in four different peritoneal dialysis fluids. Eur J Clin Microbiol Infect Dis 31:1327–1334CrossRefPubMed
16.
go back to reference Shalit I, Welch DF, San Joaquin VH, Marks MI (1985) In vitro antibacterial activities of antibiotics against Pseudomonas aeruginosa in peritoneal dialysis fluid. Antimicrob Agents Chemother 27:908–911PubMedCentralCrossRefPubMed Shalit I, Welch DF, San Joaquin VH, Marks MI (1985) In vitro antibacterial activities of antibiotics against Pseudomonas aeruginosa in peritoneal dialysis fluid. Antimicrob Agents Chemother 27:908–911PubMedCentralCrossRefPubMed
17.
18.
go back to reference Tybring L, Melchior NH (1975) Mecillinam (FL 1060), a 6beta-amidinopenicillanic acid derivative: bactericidal action and synergy in vitro. Antimicrob Agents Chemother 8:271–276PubMedCentralCrossRefPubMed Tybring L, Melchior NH (1975) Mecillinam (FL 1060), a 6beta-amidinopenicillanic acid derivative: bactericidal action and synergy in vitro. Antimicrob Agents Chemother 8:271–276PubMedCentralCrossRefPubMed
20.
go back to reference McDonald WA, Watts J, Bowmer MI (1986) Factors affecting Staphylococcus epidermidis growth in peritoneal dialysis solutions. J Clin Microbiol 24:104–107PubMedCentralPubMed McDonald WA, Watts J, Bowmer MI (1986) Factors affecting Staphylococcus epidermidis growth in peritoneal dialysis solutions. J Clin Microbiol 24:104–107PubMedCentralPubMed
21.
go back to reference Tobudic S, Kratzer C, Poeppl W, Vychytil A, Burgmann H (2011) Impact of various peritoneal dialysis solutions on the growth of common bacterial and yeast pathogens. Perit Dial Int 31:688–692CrossRefPubMed Tobudic S, Kratzer C, Poeppl W, Vychytil A, Burgmann H (2011) Impact of various peritoneal dialysis solutions on the growth of common bacterial and yeast pathogens. Perit Dial Int 31:688–692CrossRefPubMed
22.
go back to reference Richards GK, Gagnon RF, Obst G, Kostiner GB (1993) The effect of peritoneal dialysis solutions on rifampin action against Staphylococcus epidermidis in the fluid and biofilm phases of growth. Perit Dial Int 13:S341–S344PubMed Richards GK, Gagnon RF, Obst G, Kostiner GB (1993) The effect of peritoneal dialysis solutions on rifampin action against Staphylococcus epidermidis in the fluid and biofilm phases of growth. Perit Dial Int 13:S341–S344PubMed
23.
go back to reference McCormick EM, Echols RM (1987) Effect of peritoneal dialysis fluid and pH on bactericidal activity of ciprofloxacin. Antimicrob Agents Chemother 31:657–659PubMedCentralCrossRefPubMed McCormick EM, Echols RM (1987) Effect of peritoneal dialysis fluid and pH on bactericidal activity of ciprofloxacin. Antimicrob Agents Chemother 31:657–659PubMedCentralCrossRefPubMed
24.
go back to reference Patel RP, Li K, Shastri M, Wanandy T, Jose MD (2015) Stability of ampicillin and amoxicillin in peritoneal dialysis solutions. Am J Health Syst Pharm 72:13–14CrossRefPubMed Patel RP, Li K, Shastri M, Wanandy T, Jose MD (2015) Stability of ampicillin and amoxicillin in peritoneal dialysis solutions. Am J Health Syst Pharm 72:13–14CrossRefPubMed
25.
go back to reference Roberts DM, Fernando G, Singer RF, Kennedy KJ, Lawrence M, Talaulikar G (2011) Antibiotic stability in commercial peritoneal dialysis solutions: influence of formulation, storage and duration. Nephrol Dial Transplant 26:3344–3349CrossRefPubMed Roberts DM, Fernando G, Singer RF, Kennedy KJ, Lawrence M, Talaulikar G (2011) Antibiotic stability in commercial peritoneal dialysis solutions: influence of formulation, storage and duration. Nephrol Dial Transplant 26:3344–3349CrossRefPubMed
26.
go back to reference Manley HJ, McClaran ML, Bedenbaugh A, Peloquin CA (2002) Linezolid stability in peritoneal dialysis solutions. Perit Dial Int 22:419–422PubMed Manley HJ, McClaran ML, Bedenbaugh A, Peloquin CA (2002) Linezolid stability in peritoneal dialysis solutions. Perit Dial Int 22:419–422PubMed
27.
go back to reference Parra MA, Campanero MA, Sádaba B, Irigoyen A, García-López L, Fernandez-Reyes MJ et al (2013) Effect of glucose concentration on the stability of daptomycin in peritoneal solutions. Perit Dial Int 33:458–461PubMedCentralCrossRefPubMed Parra MA, Campanero MA, Sádaba B, Irigoyen A, García-López L, Fernandez-Reyes MJ et al (2013) Effect of glucose concentration on the stability of daptomycin in peritoneal solutions. Perit Dial Int 33:458–461PubMedCentralCrossRefPubMed
28.
go back to reference Peyro Saint Paul L, Albessard F, Gaillard C, Debruyne D, Ryckelynck J-P, Coquerel A et al (2011) Daptomycin compatibility in peritoneal dialysis solutions. Perit Dial Int 31:492–495CrossRefPubMed Peyro Saint Paul L, Albessard F, Gaillard C, Debruyne D, Ryckelynck J-P, Coquerel A et al (2011) Daptomycin compatibility in peritoneal dialysis solutions. Perit Dial Int 31:492–495CrossRefPubMed
29.
go back to reference Cozens RM, Tuomanen E, Tosch W, Zak O, Suter J, Tomasz A (1986) Evaluation of the bactericidal activity of beta-lactam antibiotics on slowly growing bacteria cultured in the chemostat. Antimicrob Agents Chemother 29:797–802PubMedCentralCrossRefPubMed Cozens RM, Tuomanen E, Tosch W, Zak O, Suter J, Tomasz A (1986) Evaluation of the bactericidal activity of beta-lactam antibiotics on slowly growing bacteria cultured in the chemostat. Antimicrob Agents Chemother 29:797–802PubMedCentralCrossRefPubMed
30.
go back to reference Tuomanen E, Cozens R, Tosch W, Zak O, Tomasz A (1986) The rate of killing of Escherichia coli by beta-lactam antibiotics is strictly proportional to the rate of bacterial growth. J Gen Microbiol 132:1297–1304PubMed Tuomanen E, Cozens R, Tosch W, Zak O, Tomasz A (1986) The rate of killing of Escherichia coli by beta-lactam antibiotics is strictly proportional to the rate of bacterial growth. J Gen Microbiol 132:1297–1304PubMed
31.
go back to reference Eagle H, Musselman AD (1948) The rate of bactericidal action of penicillin in vitro as a function of its concentration, and its paradoxically reduced activity at high concentrations against certain organisms. J Exp Med 88:99–131PubMedCentralCrossRefPubMed Eagle H, Musselman AD (1948) The rate of bactericidal action of penicillin in vitro as a function of its concentration, and its paradoxically reduced activity at high concentrations against certain organisms. J Exp Med 88:99–131PubMedCentralCrossRefPubMed
32.
go back to reference Stille W, Uffelmann H (1973) Paradoxic bactericidal effect of penicillins on enterococci (Eagle effect). Dtsch Med Wochenschr 98:611–613CrossRefPubMed Stille W, Uffelmann H (1973) Paradoxic bactericidal effect of penicillins on enterococci (Eagle effect). Dtsch Med Wochenschr 98:611–613CrossRefPubMed
33.
go back to reference Mascio CTM, Alder JD, Silverman JA (2007) Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells. Antimicrob Agents Chemother 51:4255–4260PubMedCentralCrossRefPubMed Mascio CTM, Alder JD, Silverman JA (2007) Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells. Antimicrob Agents Chemother 51:4255–4260PubMedCentralCrossRefPubMed
34.
go back to reference Bahte SK, Bertram A, Burkhardt O, Martens-Lobenhoffer J, Goedecke V, Bode-Böger SM et al (2010) Therapeutic serum concentrations of daptomycin after intraperitoneal administration in a patient with peritoneal dialysis-associated peritonitis. J Antimicrob Chemother 65:1312–1314CrossRefPubMed Bahte SK, Bertram A, Burkhardt O, Martens-Lobenhoffer J, Goedecke V, Bode-Böger SM et al (2010) Therapeutic serum concentrations of daptomycin after intraperitoneal administration in a patient with peritoneal dialysis-associated peritonitis. J Antimicrob Chemother 65:1312–1314CrossRefPubMed
Metadata
Title
The influence of different peritoneal dialysis fluids on the in vitro activity of ampicillin, daptomycin, and linezolid against Enterococcus faecalis
Authors
M. Kussmann
L. Schuster
M. Zeitlinger
P. Pichler
G. Reznicek
M. Wiesholzer
H. Burgmann
W. Poeppl
Publication date
01-11-2015
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 11/2015
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-015-2477-8

Other articles of this Issue 11/2015

European Journal of Clinical Microbiology & Infectious Diseases 11/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.